![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis’ Siponimod Achieves Phase III Endpoint in MS Trial
Novartis’ Siponimod Achieves Phase III Endpoint in MS Trial
![](https://www.fdanews.com/ext/resources/test/Device_Images5/stethoscope2.jpg?t=1441300884&width=430)
Novartis’ siponimod met its primary endpoint in a Phase III trial, reducing the risk of three-month confirmed disability progression in secondary progressive multiple sclerosis.
The EXPAND randomized study — the largest ever for SPMS, enrolling 1,651 patients from 31 countries — compared oral, once-daily siponimod (BAF312) to placebo. Top-line results are planned to be presented as a late-breaking oral abstract at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis on Sept. 17 in London.
Siponimod is a selective modulator of specific types of the sphingosine-1-phosphate receptor.
Upcoming Events
-
21Oct